Wedbush Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target to $20.00

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective cut by Wedbush from $21.00 to $20.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Wedbush’s target price would indicate a potential upside of 112.11% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. Royal Bank Of Canada lifted their price target on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, June 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Needham & Company LLC lowered their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Finally, Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Trading Up 4.0%

BCRX traded up $0.36 on Thursday, hitting $9.43. 1,437,874 shares of the company’s stock were exchanged, compared to its average volume of 4,984,916. The firm has a market cap of $2.40 billion, a PE ratio of -5.30 and a beta of 0.55. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.22. The stock has a fifty day moving average of $9.32 and a two-hundred day moving average of $8.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.15 by $0.15. The company had revenue of $218.25 million for the quarter, compared to analyst estimates of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue was up 33.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.15 earnings per share. On average, analysts predict that BioCryst Pharmaceuticals will post -2.58 EPS for the current year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of BCRX. Larson Financial Group LLC grew its position in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,267 shares during the period. Focus Partners Wealth bought a new position in shares of BioCryst Pharmaceuticals in the 3rd quarter valued at about $77,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Envestnet Portfolio Solutions Inc. bought a new stake in BioCryst Pharmaceuticals during the fourth quarter worth $81,000. Finally, Mercer Global Advisors Inc. ADV bought a new position in BioCryst Pharmaceuticals during the third quarter worth about $81,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.